These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38115953)

  • 1. NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V.
    Nakajima Y; Ogiwara K; Inaba K; Kitazawa T; Nogami K
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102271. PubMed ID: 38115953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
    Teranishi-Ikawa Y; Soeda T; Koga H; Yamaguchi K; Kato K; Esaki K; Asanuma K; Funaki M; Ichiki M; Ikuta Y; Ito S; Joyashiki E; Komatsu SI; Muto A; Nishimura K; Okuda M; Sanada H; Sato M; Shibahara N; Wakabayashi T; Yamaguchi K; Matsusaki A; Sampei Z; Shiraiwa H; Konishi H; Kawabe Y; Hattori K; Kitazawa T; Igawa T
    J Thromb Haemost; 2024 Feb; 22(2):430-440. PubMed ID: 37940048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
    Cramer TJ; Griffin JH; Gale AJ
    Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
    Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
    Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated protein C has a regulatory role in factor VIII function.
    Wilhelm AR; Parsons NA; Samelson-Jones BJ; Davidson RJ; Esmon CT; Camire RM; George LA
    Blood; 2021 May; 137(18):2532-2543. PubMed ID: 33512448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
    Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J
    Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretable human platelet-derived factor V originates from the plasma pool.
    Camire RM; Pollak ES; Kaushansky K; Tracy PB
    Blood; 1998 Nov; 92(9):3035-41. PubMed ID: 9787136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor V and thrombotic disease: description of a janus-faced protein.
    Nicolaes GA; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.
    Thorelli E; Kaufman RJ; Dahlbäck B
    J Biol Chem; 1998 Jun; 273(26):16140-5. PubMed ID: 9632668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
    von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
    J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.
    Noordermeer T; Chemlal S; Jansma JJ; van der Vegte V; Schutgens REG; Limper M; de Groot PG; Meijers JCM; Urbanus RT
    J Thromb Haemost; 2023 Sep; 21(9):2509-2518. PubMed ID: 37290588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
    Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
    Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del).
    Shimonishi N; Morishita E; Ogiwara K; Maruyama K; Yoshida J; Horie K; Nogami K
    J Thromb Haemost; 2024 Jun; ():. PubMed ID: 38950780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
    Heeb MJ; Kojima Y; Greengard JS; Griffin JH
    Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.
    Brophy DF; Martin EJ; Mohammed BM; Barrett JC; Kuhn JG; Nolte ME; Wiinberg B; Holmberg HL; Lund J; Salbo R; Waters EK
    Haemophilia; 2017 Nov; 23(6):941-947. PubMed ID: 28750471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.